Keryx's Auryxia meets in Phase III anemia study

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) rose $0.39 to $4.94 on Tuesday after its Auryxia ferric citrate met the primary endpoint in a Phase III

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE